CathWorks Funding: How Much Did They Raise & Key Investors

How Much Did CathWorks Raise?
Funding & Key Investors

CathWorks has successfully secured a significant capital infusion, bringing its total funding to $75.8M. This latest major strategic investment of $30M underscores the firm's pivotal role in the evolution of cardiovascular diagnostics. By leveraging advanced computational science, the company continues to attract high-profile backing from institutional investors committed to the modernization of cardiac care through non-invasive, data-driven methodologies.

The trajectory of the company, marked by consistent financial support since its Series B round, reflects a robust growth narrative. As the organization transitions through its current lifecycle stage, this influx of capital serves as a catalyst for scaling its proprietary software platform, which is designed to optimize clinical decision-making in coronary artery disease management.

What is CathWorks?

CathWorks

Software

Healthcare Software

Business Services

CathWorks operates at the intersection of medical technology and computational physiology. The company specializes in developing sophisticated software solutions that enhance the precision of coronary angiography. By providing physicians with objective, functional assessments of coronary blood flow, the platform eliminates the historical reliance on invasive pressure wires, thereby streamlining routine cardiac catheterization procedures. This innovation not only improves patient outcomes but also addresses critical inefficiencies in hospital workflows, positioning CathWorks as a leader in the digital transformation of interventional cardiology.

How much funding has CathWorks raised?

CathWorks has raised a total of $75.8M across 3 funding rounds:

2017

Series B

$15.8M

2019

Series C

$30M

2021

Series D

$30M

Series B (2017): $15.8M with participation from Quark Ventures, BioStar Capital, TriVentures, Pontifax, Planven Investments, and Corundum Open Innovation

Series C (2019): $30M led by Deerfield Management

Series D (2021): $30M, investors not publicly disclosed

Key Investors in CathWorks

Deerfield Management

Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the ecosystem with flexible funding models.

Quark Ventures

Quark Venture LP is a venture capital company focused on equity financing of innovative biotechnology companies with breakthrough technology platforms.

BioStar Capital

BioStar Capital is a visionary healthcare investor focused on transformative medical devices, combining business acumen with deep clinical expertise.

What's next for CathWorks?

With the recent injection of capital, CathWorks is well-positioned to accelerate its market penetration and expand its clinical footprint. The strategic focus will likely center on deepening the integration of its computational platform into global cardiac care standards. By prioritizing the scalability of its diagnostic tools, the company aims to solidify its market position, potentially paving the way for further commercial expansion and the development of next-generation imaging technologies that continue to redefine the standard of care for cardiovascular patients worldwide.

See full CathWorks company page

See More Financial Insights